Document is current
Any future updates will be listed below
-
Authors
Nakayama, Masanori https://orcid.org/0000-0002-6757-897X
Furuya, Takefumi https://orcid.org/0000-0001-7771-2813
Inoue, Eisuke https://orcid.org/0000-0002-1652-7769
Tanaka, Eiichi https://orcid.org/0000-0003-2850-326X
Ikari, Katsunori https://orcid.org/0000-0001-9066-2005
Yamanaka, Hisashi https://orcid.org/0000-0001-8453-6731
Harigai, Masayoshi https://orcid.org/0000-0002-6418-2603
- License Information
-
More Information
Article History
Received: 16 February 2021
Accepted: 12 July 2021
First Online: 3 August 2021
Declarations
:
: The IORRA study was approved by the Ethical committee of Tokyo Women’s Medical University (No. 2922-R16).
: Informed consent was obtained from all patients at the time of each survey.
: MN has served on speakers’ bureaus for Asahi Kasei Pharma Corporation, Bristol-Myers Squibb K.K., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Shionogi & Co., Ltd. and Takeda Pharmaceutical Co., Ltd. TF has served on speakers’ bureaus for Ayumi Pharmaceutical Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., and Teijin Pharma. EI has received lecture fees from Bristol-Myers Squibb and Pfizer Japan Inc. ET has served on speakers’ bureaus for AbbVie, Ayumi Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku, Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. KI has served on speakers’ bureaus for AbbVie, Astellas Pharma Inc., Asahi Kasei Pharma Corporation, Ayumi Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Hisamitsu Pharmaceutical Co., Inc., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Taisho Toyama Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd. HY has received speaker fee from Astellas, Bristol-Meyers-Squibb, Eisai Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and YL Bio. MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekiui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. These sponsors were not involved in the following aspects: study design; collection, analysis, and interpretation of data; writing of the paper; and/or the decision to submit for publication.
